CA2886000C - Quinazolinone derivatives as parp inhibitors - Google Patents
Quinazolinone derivatives as parp inhibitors Download PDFInfo
- Publication number
- CA2886000C CA2886000C CA2886000A CA2886000A CA2886000C CA 2886000 C CA2886000 C CA 2886000C CA 2886000 A CA2886000 A CA 2886000A CA 2886000 A CA2886000 A CA 2886000A CA 2886000 C CA2886000 C CA 2886000C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- compounds
- methyl
- quinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006707 | 2012-09-26 | ||
| EP12006707.9 | 2012-09-26 | ||
| PCT/EP2013/002577 WO2014048532A1 (en) | 2012-09-26 | 2013-08-27 | Quinazolinone derivatives as parp inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2886000A1 CA2886000A1 (en) | 2014-04-03 |
| CA2886000C true CA2886000C (en) | 2020-11-10 |
Family
ID=47002492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2886000A Active CA2886000C (en) | 2012-09-26 | 2013-08-27 | Quinazolinone derivatives as parp inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9388142B2 (enExample) |
| EP (1) | EP2900643B1 (enExample) |
| JP (1) | JP6276769B2 (enExample) |
| KR (1) | KR102200628B1 (enExample) |
| CN (1) | CN104662006B (enExample) |
| AR (1) | AR092670A1 (enExample) |
| AU (1) | AU2013324681B2 (enExample) |
| BR (1) | BR112015006524A8 (enExample) |
| CA (1) | CA2886000C (enExample) |
| ES (1) | ES2654464T3 (enExample) |
| IL (1) | IL237840A (enExample) |
| MX (1) | MX362855B (enExample) |
| RU (1) | RU2650107C2 (enExample) |
| SG (1) | SG11201502120XA (enExample) |
| WO (1) | WO2014048532A1 (enExample) |
| ZA (1) | ZA201502838B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102072041B1 (ko) | 2011-12-22 | 2020-01-31 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체 |
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PT2861611T (pt) | 2012-05-25 | 2016-10-11 | Janssen Sciences Ireland Uc | Nucleósidos de espirooxetano de uracilo |
| US9243022B2 (en) | 2012-12-21 | 2016-01-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CA2922469A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| JP6899323B2 (ja) | 2014-10-14 | 2021-07-07 | ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー | 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| CN106432103A (zh) * | 2016-09-14 | 2017-02-22 | 信阳师范学院 | 一种喹唑酮类化合物及其制备方法 |
| US11066420B2 (en) | 2017-05-01 | 2021-07-20 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof |
| WO2019131794A1 (ja) * | 2017-12-27 | 2019-07-04 | 公益財団法人がん研究会 | 抗がん剤 |
| WO2019131798A1 (ja) * | 2017-12-27 | 2019-07-04 | 国立研究開発法人理化学研究所 | 新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤 |
| US20220348549A1 (en) * | 2019-08-28 | 2022-11-03 | Hoffmann-La Roche Inc. | Quinazoline compounds for the treatment and prophylaxis of hepatitis b virus disease |
| KR102969020B1 (ko) * | 2020-10-29 | 2026-05-22 | 한국화학연구원 | 퀴나졸린-4(3h)-온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 grk5 활성 관련 질환의 예방 또는 치료용 약학 조성물 |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025221809A1 (en) * | 2024-04-16 | 2025-10-23 | Eluciderm Inc. | 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases |
| CN121226265B (zh) * | 2025-09-29 | 2026-05-26 | 亳州学院 | 一种含喹唑啉酮片段的酰腙类化合物及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9702701D0 (en) * | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO1999018077A1 (en) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| AU2003252314A1 (en) * | 2002-08-09 | 2004-02-25 | Kyorin Pharmaceutical Co., Ltd. | 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| WO2006098969A2 (en) * | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Quinazolinone t-type calcium channel antagonists |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| BR112013005223A2 (pt) * | 2010-09-03 | 2016-05-03 | Bayer Ip Gmbh | "pirimidinonas e dihidropirimidinonas fusionadas substituídas." |
-
2013
- 2013-08-27 MX MX2015003570A patent/MX362855B/es active IP Right Grant
- 2013-08-27 CN CN201380050421.9A patent/CN104662006B/zh active Active
- 2013-08-27 CA CA2886000A patent/CA2886000C/en active Active
- 2013-08-27 WO PCT/EP2013/002577 patent/WO2014048532A1/en not_active Ceased
- 2013-08-27 SG SG11201502120XA patent/SG11201502120XA/en unknown
- 2013-08-27 EP EP13756318.5A patent/EP2900643B1/en active Active
- 2013-08-27 AU AU2013324681A patent/AU2013324681B2/en active Active
- 2013-08-27 JP JP2015533466A patent/JP6276769B2/ja active Active
- 2013-08-27 US US14/431,632 patent/US9388142B2/en active Active
- 2013-08-27 RU RU2015115576A patent/RU2650107C2/ru active
- 2013-08-27 BR BR112015006524A patent/BR112015006524A8/pt not_active Application Discontinuation
- 2013-08-27 KR KR1020157010728A patent/KR102200628B1/ko not_active Expired - Fee Related
- 2013-08-27 ES ES13756318.5T patent/ES2654464T3/es active Active
- 2013-09-25 AR ARP130103430A patent/AR092670A1/es active IP Right Grant
-
2015
- 2015-03-19 IL IL237840A patent/IL237840A/en active IP Right Grant
- 2015-04-24 ZA ZA2015/02838A patent/ZA201502838B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102200628B1 (ko) | 2021-01-08 |
| AU2013324681B2 (en) | 2017-08-10 |
| AU2013324681A1 (en) | 2015-05-07 |
| JP2015535831A (ja) | 2015-12-17 |
| MX362855B (es) | 2019-02-20 |
| ZA201502838B (en) | 2017-11-29 |
| JP6276769B2 (ja) | 2018-02-07 |
| EP2900643B1 (en) | 2017-09-27 |
| ES2654464T3 (es) | 2018-02-13 |
| EP2900643A1 (en) | 2015-08-05 |
| US20150239850A1 (en) | 2015-08-27 |
| MX2015003570A (es) | 2015-06-22 |
| WO2014048532A1 (en) | 2014-04-03 |
| BR112015006524A2 (pt) | 2017-07-04 |
| US9388142B2 (en) | 2016-07-12 |
| RU2650107C2 (ru) | 2018-04-09 |
| CA2886000A1 (en) | 2014-04-03 |
| KR20150063474A (ko) | 2015-06-09 |
| SG11201502120XA (en) | 2015-04-29 |
| IL237840A (en) | 2017-05-29 |
| AR092670A1 (es) | 2015-04-29 |
| CN104662006B (zh) | 2017-10-24 |
| CN104662006A (zh) | 2015-05-27 |
| RU2015115576A (ru) | 2016-11-20 |
| HK1210777A1 (en) | 2016-05-06 |
| BR112015006524A8 (pt) | 2019-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2900643B1 (en) | Quinazolinone derivatives as parp inhibitors | |
| EP2882714B1 (en) | (aza-)isoquinolinone derivatives | |
| EP2844659B1 (en) | Pyrrolotriazinone derivatives | |
| EP2831077B1 (en) | Bicyclic pyrazinone derivatives | |
| CA2863991C (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| AU2009306795B2 (en) | Azaindole derivative | |
| EP2976328B1 (en) | Piperazine derivatives as fasn inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180827 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250724 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250724 |